Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like proteaseFDA 승인 항바이러스제, 항생제, 구충제, 항산화제 및 SARS-CoV-2 파파인 유사 프로테아제에 대한 세포 보호제의 용도 변경Article Published on 2021-09-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] SARS, 신약개발, 진단, 치료제, [키워드] 6-mercaptopurine ACE acting analysis Antacid Antibiotics anticancer drugs antimicrobial antioxidant antioxidants Antiviral antivirals approved drug benzimidazole binding affinities binding affinity binding energy binding pattern binding patterns blocker bypassing candesartan Cell contagious coronavirus coronavirus disease coronavirus disease 19 COVID-19 COVID-19 patient COVID-19 patients Critical demonstrated docking score doripenem drug Drug discovery Drug repurposing drugs expected Famotidine fatal disease FDA-approved drugs followed by Guidance highest inhibitor list losartan MD simulations mercaptopurine molecular molecular dynamics moroxydine NAD+ oxiglutatione Papain Papain-like protease pharmacokinetic Phenformin PLPro primer protease Protease. Protective provided quercetin quercitrin receptor repurposing Ritonavir Safe SARS CoV SARS-CoV-2 sulfaguanidine surface area systemically Toxicity treat Vaccine development valsartan was used zanamivir [DOI] 10.1080/07391102.2020.1784291 PMC 바로가기 [Article Type] Article
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)증상이 있는 SARS-CoV-2 감염(COVID-19)이 있는 고령자의 가정 치료: 여러 가지 실험적 치료의 효능과 내약성을 평가하기 위한 MAMS(Multi-Arm Multi-Stage) 무작위 시험에 대한 연구 프로토콜의 구조화된 요약 65세 이상 외래 환자의 입원 또는 사망 위험 감소(COVERAGE 시험)Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 6-mercaptopurine Abnormalities ACEi added age amodiaquine analysis Analysis antrafenine approved ARB ARBs Arm azathioprine Blinding Bordeaux Caregivers Chloroquine chronic hepatitis Chronic kidney disease citalopram clinical Colitis Combination comparator complex conducted Control control arm COVID-19 COVID-19 pandemic criteria CYP3A4 cytochrome P450 Dasatinib death Dementia dialysis dissemination Domperidone drug Duchy Efficacy element enrolled enrolment Enterocolitis escitalopram EudraCT Evidence exclusion criteria experimental arm experimental drug Experimental drugs Favipiravir feasibility Final final analysis first symptom first symptoms floctafenine France French futility galactose GFR glafenine Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase glucose-6-phosphate dehydrogenase deficiency Grand duchy halofantrine Health Insurance heart rate hepatic Hepatic porphyria home hospital hospitalisation Hydroxychloroquine hydroxyzine hypersensitivity Hyperuricemia Ileus Imatinib immunological incidence Inclusion increase in inducer inhibitor Interim analyses interim analysis intervals investigator investigators Isoenzyme Kidney disease Lactase Lactose liver failure Long Long QT syndrome Luxembourg malabsorption mefloquine mercaptopurine metabolism multi multi-arm nasopharyngeal Nasopharyngeal swab New Nilotinib not blinded number nursing home nursing homes objective Older Open-label open-label trial other treatment other treatments outcome Outpatient P450 Paris participant Patient performed phase Piperaquine Positive test Prevent primary care Primary outcome proportion protocol pyrazinamide QTc interval randomisation randomised Randomized Randomly receive recruited Region Registered regulatory authority repaglinide replaced REPLACED BY reported Repurposed drug residence Safety Monitoring Board Sample size SARS-CoV-2 SARS-COV-2 infection scale Stage Standard statistician statisticians status stratified Study protocol submitted symptomatic SARS-CoV-2 infection Tablet telmisartan tested theophylline Toxicity Trace element trace elements treated Treatment treatment arm Trial Trial registration Version virus Virus Disease Vitamin vitamins Warfarin [DOI] 10.1186/s13063-020-04619-1 PMC 바로가기 [Article Type] Letter